Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2025 09:01 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE...
November 07, 2025 09:00 ET | Source: Coherus Oncology, Inc.

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114...
November 04, 2025 11:45 ET | Source: Transgene S.A.

Les nouvelles données d’immunologie de la Phase I de TG4050 présentées au SITC 2025 démontrent son potentiel prometteur à réduire le risque de récidive

Les nouvelles données mettent en évidence les éléments clés du mécanisme d’action de TG4050, qui induit des réponses immunitaires durables (lymphocytes T CD8+) chez des patients atteints d’un cancer...
November 04, 2025 11:45 ET | Source: Transgene S.A.

New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse

New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] patients Comprehensive immunogenicity data demonstrate TG4050’s...
November 04, 2025 09:05 ET | Source: Abalos Therapeutics GmbH

Abalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025

Abalos to present preclinical data on ABX-001 and its potential to further intensify anti-tumoral effects when combined with bispecific T-cell engagers
October 03, 2025 11:45 ET | Source: Transgene S.A.

Transgene présente de nouvelles données d’immunologie de la Phase I de TG4050, son vaccin thérapeutique individualisé, au SITC 2025

Strasbourg, France, le 3 octobre 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs...
October 03, 2025 11:45 ET | Source: Transgene S.A.

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025

Strasbourg, France, October 3, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present...
October 03, 2025 09:05 ET | Source: Coherus Oncology, Inc.

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for...